v3.26.1
Investment in MiNK Therapeutics, Inc. - Summarized Balance Sheet Information and Results of Operations (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
Investment Company, Nonconsolidated Subsidiary [Line Items]      
Current assets $ 95,284   $ 133,436
Current liabilities 249,237   $ 323,489
Net loss attributable to Agenus 39,206 $ (26,370)  
MiNK Therapeutics, Inc.      
Investment Company, Nonconsolidated Subsidiary [Line Items]      
Current assets 10,022    
Non-current assets 355    
Current liabilities 7,287    
Non-current liabilities 15,776    
Net loss (2,742)    
Net loss attributable to Agenus $ (1,206)